Raymond James & Associates Abb Vie Inc. Call Options Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

Call Options

23 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $1.26 Million - $1.51 Million	9,100 Added 31.6%	37,900 $6.13 Million
Q3 2022 Oct 25, 2022	SELL	$134.21 - $153.93 $1.19 Million - $1.37 Million	-8,900 Reduced 23.61%	28,800 $7,000
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $1.54 Million - $1.96 Million	-11,200 Reduced 22.9%	37,700 $265,000
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $1.54 Million - $1.92 Million	-11,700 Reduced 19.31%	48,900 $431,000
Q4 2021 Feb 08, 2022	SELL	$107.43 - $135.93 $676,809 - $856,359	-6,300 Reduced 9.42%	60,600 $560,000
Q3 2021 Nov 02, 2021	BUY	$106.4 - $120.78 $1.95 Million - $2.21 Million	18,300 Added 37.65%	66,900 $51,000
Q2 2021 Aug 11, 2021	BUY	$105.21 - $117.21 $4.04 Million - $4.5 Million	38,400 Added 376.47%	48,600 $37,000
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $4.86 Million - $5.35 Million	-47,500 Reduced 82.32%	10,200 $3,000
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $2.12 Million - $2.87 Million	26,400 Added 84.35%	57,700 $285,000
Q3 2020 Nov 04, 2020	SELL	$85.91 - $100.83 $214,775 - $252,075	-2,500 Reduced 7.4%	31,300 $36,000
Q2 2020 Jul 28, 2020	BUY	$73.37 - $98.18 $80,707 - $107,998	1,100 Added 3.36%	33,800 $50,000
Q1 2020 Apr 21, 2020	BUY	$64.5 - $97.79 $1.31 Million - $1.99 Million	20,300 Added 163.71%	32,700 $8,000
Q4 2019 Feb 12, 2020	SELL	$72.13 - $90.25 $64,916 - $81,225	-900 Reduced 6.77%	12,400 $26,000
Q3 2019 Nov 07, 2019	SELL	$62.98 - $75.72 $6,298 - $7,572	-100 Reduced 0.75%	13,300 $36,000
Q2 2019 Aug 06, 2019	SELL	$65.7 - $83.98 $4.68 Million - $5.98 Million	-71,200 Reduced 84.16%	13,400 $2,000
Q1 2019 May 06, 2019	BUY	$77.14 - $90.79 $1.14 Million - $1.34 Million	14,800 Added 21.2%	84,600 $12,000
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $3.21 Million - $3.96 Million	-41,200 Reduced 37.12%	69,800 $87,000
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $2.42 Million - $2.69 Million	-27,200 Reduced 19.68%	111,000 $39,000
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $1.37 Million - $1.63 Million	15,300 Added 12.45%	138,200 $44,000
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $3.1 Million - $4.15 Million	-33,700 Reduced 21.52%	122,900 $231,000
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $4.01 Million - $4.4 Million	-44,800 Reduced 22.24%	156,600 $452,000
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $3.97 Million - $5.07 Million	56,800 Added 39.28%	201,400 $1.59 Million
Q2 2017 Aug 14, 2017	BUY	N/A	144,600	144,600 $307,000

Others Institutions Holding ABBV

# of Institutions

3,694

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

Vanguard Group Inc Valley Forge, PA

171M
Shares

$33.2 Billion
0.57% of portfolio
Black Rock Inc. New York, NY

136M
Shares

$26.6 Billion
0.54% of portfolio
State Street Corp Boston, MA

77.8M
Shares

$15.2 Billion
0.59% of portfolio
Jpmorgan Chase & CO New York, NY

53.6M
Shares

$10.4 Billion
0.81% of portfolio
Capital International Investors Los Angeles, CA

38.6M
Shares

$7.52 Billion
1.4% of portfolio

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $344B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account